The potential of CYP46A1 as a novel therapeutic target for neurological disorders: An updated review of mechanisms

Cholesterol is a key component of the cell membrane that impacts the permeability, fluidity, and functions of membrane-bound proteins. It also participates in synaptogenesis, synaptic function, axonal growth, dendrite outgrowth, and microtubule stability. Cholesterol biosynthesis and metabolism are in balance in the brain. Its metabolism in the brain is mediated mainly by CYP46A1 or cholesterol 24-hydroxylase. It is responsible for eliminating about 80% of the cholesterol excess from the human brain. CYP46A1 converts cholesterol to 24S-hydroxycholesterol (24HC) that readily crosses the blood-brain barrier and reaches the liver for the final elim-ination process. Studies show that cholesterol and 24HC levels change during neurological diseases and condi-tions. So, it was hypothesized that inhibition or activation of CYP46A1 would be an effective therapeutic strategy. Accordingly, preclinical studies, using genetic and pharmacological interventions, assessed the role of CYP46A1 in main neurodegenerative disorders such as Parkinson's disease, Huntington's disease, Alzheimer's disease, multiple sclerosis, spinocerebellar ataxias, and amyotrophic lateral sclerosis. In addition, its role in seizures and brain injury was evaluated. The recent development of soticlestat, as a selective and potent CYP46A1 inhibitor, with significant anti-seizure effects in preclinical and clinical studies, suggests the impor-tance of this target for future drug developments. Previous studies have shown that both activation and inhi-bition of CYP46A1 are of therapeutic value. This article, using recent studies, highlights the role of CYP46A1 in various brain diseases and insults.

Automated summary

Cholesterol is a vital component of the cell membrane that affects membrane properties and functions. Its metabolism in the brain is regulated by CYP46A1, which converts cholesterol to 24S-hydroxycholesterol for elimination. Studies suggest that changes in cholesterol levels may be associated with neurological diseases, and targeting CYP46A1 could be a therapeutic approach. Preclinical studies have investigated the role of CYP46A1 in various brain disorders and injuries, and a selective inhibitor called soticlestat has shown promising anti-seizure effects. Both activation and inhibition of CYP46A1 have therapeutic potential, as demonstrated by previous studies.